# # # #
In September, a small biotech company called CuraSen announced that they had dosed the first participant in a clinical trial of their new experimental drug for Parkinson’s.
This news did not garner a lot of attention, but was of great interest to us here at the SoPD because the drug – currently named CST-2032 – is the first of a novel class of drug to be tested in Parkinson’s.
It also represents a shift in our approach to disease modification in neurodegenerative conditions (like Parkinson’s) as the focus moves away from solely being on the dopamine neurons.
In today’s post, we will look at what CST-2032 is, what evidence exists that supports this drug going into clinical trial, and why it might represent a turning point in how we approach the treatment of Parkinson’s.
# # # #
The first thing you notice when you go to the CuraSen website are the words “Think, again“.
A curious introduction to a biotech, but it grabs the attention.
Next – and I don’t want to ruin things for anyone (Spoiler alert!) – the words fade away…
… only to be replaced by: “Rethinking neurodegeneration”
And with a little bit of digging, you realise that it is interesting.
Why is Curasen interesting?
Curasen is a California-based biotech taking a slightly different approach towards neurodegenerative conditions like Parkinson’s.
What are they doing?